High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies. Cell and ...

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...

Training deficits in STS brachytherapy stem primarily from limited resident case exposure, despite broad perceived importance ...

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

Reproductive-care access remains unsettled as mifepristone telehealth/mail distribution is temporarily protected by the ...

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...

This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

Compared with usual care, a dementia care management program improved various cost of care and utilization metrics in a Medicare managed care population at 12 months. Objectives: To examine a 12-month ...